Edgar Filing: PERKINELMER INC

PKI-7.01.2012-10Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________________

FORM 10-Q

_______________________________________

(Mark One)



ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 1, 2012



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number 001-5075

_______________________________________

PerkinElmer, Inc.

(Exact name of Registrant as specified in its Charter)

_______________________________________



Massachusetts		04-2052042
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

940 Winter Street

Waltham, Massachusetts 02451

(Address of principal executive offices) (Zip code)

(781) 663-6900

(Registrant’s telephone number, including area code)

_______________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	ý	Accelerated filer	¨

Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No ý

As of August 2, 2012, there were outstanding 114,071,095 shares of common stock, $1 par value per share.

Table of Contents

TABLE OF CONTENTS



		Page
PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	3
	Condensed Consolidated Statements of Operations	3
	Condensed Consolidated Statements of Comprehensive Income	4
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Statements of Cash Flows	5
	Notes to Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	7
	Overview	7
	Critical Accounting Policies and Estimates	8
	Consolidated Results of Continuing Operations	8
	Reporting Segment Results of Continuing Operations	15
	Liquidity and Capital Resources	17
	Dividends	20
	Effects of Recently Adopted Accounting Pronouncements	20
	Effects of Recently Issued Accounting Pronouncements	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21

Item 4.	Controls and Procedures	21

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	23

Item 1A.	Risk Factors	23

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30

Item 6.	Exhibits	31

Signatures		32

Exhibit Index		33

Table of Contents

PART I. FINANCIAL INFORMATION


Item 1.	Financial Statements

PERKINELMER, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)



	Three Months Ended					Six Months Ended
	July 1, 2012		July 3, 2011			July 1, 2012		July 3, 2011
			(As adjusted)					(As adjusted)
	(In thousands, except per share data)
Product revenue	$	364,243	$	326,419		$	721,436	$	632,545
Service revenue	157,547		152,646			311,244		293,698
Total revenue	521,790		479,065			1,032,680		926,243
Cost of product revenue	186,442		176,080			372,899		333,331
Cost of service revenue	96,554		93,791			188,973		183,407
Total cost of revenue	282,996		269,871			561,872		516,738
Selling, general and administrative expenses	149,735		138,403			306,584		271,098
Research and development expenses	34,069		28,032			66,693		54,217
Restructuring and contract termination charges, net	5,203		3,340			11,362		3,340
Operating income from continuing operations	49,787		39,419			86,169		80,850
Interest and other expense, net	11,358		4,271			24,188		10,027
Income from continuing operations before income taxes	38,429		35,148			61,981		70,823
Provision for income taxes	4,861		6,047			6,337		14,431
Net income from continuing operations	33,568		29,101			55,644		56,392
Gain (loss) on disposition of discontinued operations before income taxes	482		(157		)	1,017		(1,741		)
Provision for (benefit from) income taxes on disposition of discontinued operations	417		(817		)	459		(23		)
Net income (loss) from discontinued operations and dispositions	65		660			558		(1,718		)
Net income	$	33,633	$	29,761		$	56,202	$	54,674
Basic earnings (loss) per share:
Net income from continuing operations	$	0.30	$	0.26		$	0.49	$	0.50
Net income (loss) from discontinued operations and dispositions	—		0.01			—		(0.02		)
Net income	$	0.30	$	0.26		$	0.50	$	0.48
Diluted earnings (loss) per share:
Net income from continuing operations	$	0.29	$	0.26		$	0.49	$	0.49
Net income (loss) from discontinued operations and dispositions	—		0.01			—		(0.02		)
Net income	$	0.29	$	0.26		$	0.49	$	0.48
Weighted average shares of common stock outstanding:
Basic	113,515		112,494			113,306		113,246
Diluted	114,578		113,623			114,348		114,381
Cash dividends per common share	$	0.07	$	0.07		$	0.14	$	0.14

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PERKINELMER, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)



	Three Months Ended						Six Months Ended
	July 1, 2012			July 3, 2011			July 1, 2012			July 3, 2011
				(As adjusted)						(As adjusted)
	(In thousands)
Net income	$	33,633		$	29,761		$	56,202		$	54,674
Other comprehensive (loss) income
Foreign currency translation adjustments, net of tax	(30,344		)	16,320			(16,578		)	63,611
Reclassification adjustments for losses on derivatives included in net income, net of tax	299			299			598			598
Unrealized (losses) gains on securities, net of tax	(13		)	(32		)	22			18
Other comprehensive (loss) income	(30,058		)	16,587			(15,958		)	64,227
Comprehensive income	$	3,575		$	46,348		$	40,244		$	118,901

The accompanying notes are an integral part of these condensed consolidated financial statements.

PERKINELMER, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)



	July 1, 2012			January 1, 2012
	(In thousands, except share data)
Current assets:
Cash and cash equivalents	$	171,403		$	142,342
Accounts receivable, net	389,466			409,888
Inventories, net	244,436			240,763
Other current assets	92,293			69,023
Current assets of discontinued operations	202			202
Total current assets	897,800			862,218
Property, plant and equipment, net:
At cost	456,830			451,953
Accumulated depreciation	(289,653		)	(277,386		)
Property, plant and equipment, net	167,177			174,567
Marketable securities and investments	1,102			1,105
Intangible assets, net	613,009			661,607
Goodwill	2,080,031			2,093,626
Other assets, net	41,818			41,075
Total assets	$	3,800,937		$	3,834,198
Current liabilities:
Accounts payable	$	174,028		$	173,153
Accrued restructuring costs	15,189			13,958
Accrued expenses	397,353			411,526
Current liabilities of discontinued operations	1,115			1,429
Total current liabilities	587,685			600,066
Long-term debt	911,043			944,908
Long-term liabilities	416,879			447,008
Total liabilities	1,915,607			1,991,982
Commitments and contingencies (see Note 18)
Stockholders’ equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	—			—
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 114,060,000 shares and 113,157,000 shares at July 1, 2012 and at January 1, 2012, respectively	114,060			113,157
Capital in excess of par value	182,321			164,290
Retained earnings	1,550,821			1,510,683
Accumulated other comprehensive income	38,128			54,086
Total stockholders’ equity	1,885,330			1,842,216
Total liabilities and stockholders’ equity	$	3,800,937		$	3,834,198

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PERKINELMER, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)



	Six Months Ended
	July 1, 2012			July 3, 2011
				(As adjusted)
	(In thousands)
Operating activities:
Net income	$	56,202		$	54,674
Add: net (income) loss from discontinued operations and dispositions, net of income taxes	(558		)	1,718
Net income from continuing operations	55,644			56,392
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and contract termination charges, net	11,362			3,340
Depreciation and amortization	64,163			50,601
Stock-based compensation	10,252			7,960
Amortization of deferred debt issuance costs	1,745			1,270
Amortization of acquired inventory revaluation	4,774			378
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	13,473			3,904
Inventories, net	(12,652		)	(3,566		)
Accounts payable	1,645			(19,838		)
Excess tax benefit from exercise of equity grants	(1,139		)	(8,591		)
Accrued expenses and other	(56,594		)	10,332
Net cash provided by operating activities of continuing operations	92,673			102,182
Net cash used in operating activities of discontinued operations	(744		)	(7,631		)
Net cash provided by operating activities	91,929			94,551
Investing activities:
Capital expenditures	(11,449		)	(15,970		)
Changes in restricted cash balances	200			420
Payments for acquisitions and investments, net of cash and cash equivalents acquired	—			(310,351		)
Net cash used in investing activities of continuing operations	(11,249		)	(325,901		)
Net cash provided by investing activities of discontinued operations	988			28,252
Net cash used in investing activities	(10,261		)	(297,649		)
Financing activities:
Payments on debt	(244,000		)	(247,000		)
Proceeds from borrowings	210,000			494,000
Payments of debt issuance costs	(416		)	—
Payments on other credit facilities	—			(2,303		)
Payments for acquisition-related contingent consideration	(9,343		)	(137		)
Excess tax benefit from exercise of equity grants	1,139			8,591
Proceeds from stock options exercised	11,746			23,552
Purchases of common stock	(2,063		)	(109,997		)
Dividends paid	(15,891		)	(15,997		)
Net cash (used in) provided by financing activities of continuing operations	(48,828		)	150,709
Net cash used in financing activities of discontinued operations	—			(1,908		)
Net cash (used in) provided by financing activities	(48,828		)	148,801
Effect of exchange rate changes on cash and cash equivalents	(3,779		)	29,419
Net increase (decrease) in cash and cash equivalents	29,061			(24,878		)
Cash and cash equivalents at beginning of period	142,342			420,086
Cash and cash equivalents at end of period	$	171,403		$	395,208

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PERKINELMER, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1: Basis of Presentation

The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), without audit, in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended January 1, 2012, filed with the SEC (the “2011 Form 10-K”). The balance sheet amounts at January 1, 2012 in this report were derived from the Company’s audited 2011 consolidated financial statements included in the 2011 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three and six months ended July 1, 2012 and July 3, 2011, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company has evaluated subsequent events from July 1, 2012 through the date of the issuance of these condensed consolidated financial statements and has determined that no material subsequent events have occurred that would affect the information presented in these condensed consolidated financial statements or would require additional disclosure.

Change in Accounting for Pension and Other Postretirement Benefits: During the fourth quarter of fiscal year 2011 the Company changed its method of recognizing defined benefit pension and other postretirement benefit costs. Accordingly, the financial data for all periods presented has been retrospectively adjusted to reflect the effect of these accounting changes. Actuarial gains and losses are measured annually as of fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. This change in accounting method for pension and other postretirement benefits is described in more detail in Note 1 to the Company’s audited consolidated financial statements filed with the 2011 Form 10-K. For the three and six months ended July 3, 2011 the retrospective changes in recognizing defined benefit pension and other postretirement benefit costs increased operating income from continuing operations by $1.9 million and $4.0 million, net income by $1.2 million and $2.6 million, basic earnings per share by $0.01 and $0.02, diluted earnings per share by $0.01 and $0.02, and other comprehensive (loss) income by $1.3 million and $2.9 million, respectively. There were no changes to the previously reported cash flows from operating, investing or financing activities for the three and six months ended July 3, 2011.

Immaterial Restatement: As disclosed in the Company's 2011 Form 10-K, prior to the fiscal year 2011 annual financial statements, the Company had reported revenue and cost of revenue as single line items and had not broken out product and service revenue and related cost of revenue separately. Accordingly, the Company has restated previously reported revenue and cost of revenue for the three and six months ended July 3, 2011 to separately report product revenue, service revenue, and the related cost of product revenue and cost of service revenue.

Recently Adopted Accounting Pronouncements: During the first quarter of fiscal year 2012 the Company adopted new guidance applicable to certain of its health care businesses that recognize patient service revenue at the time the services are rendered where the Company does not assess the patient's ability to pay at the time of the sale. The new guidance requires the Company to present the provision for bad debts related to such revenue as a deduction from revenue (net of contractual allowances and discounts) on the statements of operations. The effects of the adoption on the Company's condensed consolidated statements of operations resulted in a decrease to revenue and a decrease to selling, general and administrative expenses of $0.7 million and $1.4 million for the three and six months ended July 1, 2012, respectively, and a decrease to revenue and a decrease to selling, general and administrative expenses of $0.4 million and $1.1 million for the three and six months ended July 3, 2011, respectively. Accordingly, the financial data for all periods presented has been retrospectively adjusted to reflect the effect of these accounting changes.

Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, the Company believes that such recently issued pronouncements will not have a significant impact on the Company’s condensed consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.

Note 2: Business Combinations

Acquisition of Caliper Life Sciences, Inc. In November 2011, the Company acquired all of the outstanding stock of Caliper Life Sciences, Inc. (“Caliper”). Caliper is a provider of imaging and detection solutions for life sciences research, diagnostics and environmental markets. Caliper develops and sells integrated systems, consisting of instruments, software, reagents, laboratory automation tools, and assay development and discovery services, primarily to pharmaceutical, biotechnology, and diagnostics companies, and government and other not-for-profit research institutions. The Company expects this acquisition to enhance its molecular imaging and detection technologies and to complement its offerings in life science, diagnostics, environmental and food markets. The Company paid the shareholders of Caliper $646.3 million in cash for the stock of Caliper. The Company financed the acquisition by issuing $500.0 million aggregate principal amount of senior unsecured notes due 2021 in a registered public offering and received approximately $496.9 million of net proceeds from the issuance, with the remainder of the purchase price paid from available cash. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company has reported the operations for this acquisition within the results of the Company’s Human Health segment from the acquisition date. The total purchase price has been preliminarily allocated to the estimated fair values of assets acquired and liabilities assumed as follows:



	Caliper (Preliminary)
	(In thousands)
Fair value of business combination:
Cash payments	$	646,317
Less: cash acquired	(43,576		)
Total	$	602,741
Identifiable assets acquired and liabilities assumed:
Current assets	$	55,756
Property, plant and equipment	14,580
Identifiable intangible assets:
Core technology	52,000
Trade names	14,200
Licenses	18,000
Customer relationships	93,000
Goodwill	352,494
Deferred taxes	54,068
Deferred revenue	(7,825		)
Liabilities assumed	(43,532		)
Total	$	602,741

The weighted average amortization periods of identifiable definite-lived intangible assets were 5.0 years for core technology, 6.0 years for licenses, 7.0 years for customer relationships, and 7.0 years for trade names.

The following unaudited pro forma information presents the combined financial results for the Company and Caliper as if the acquisition of Caliper had been completed as of January 2, 2011:



	Three Months Ended		Six Months Ended
	July 3, 2011		July 3, 2011
	(In thousands)
Pro Forma Statement of Operations Information (Unaudited):
Revenue	$	517,102	$	999,761
Net income from continuing operations	17,686		33,543
Basic earnings per share:
Continuing operations	$	0.16	$	0.30
Diluted earnings per share:
Continuing operations	$	0.16	$	0.29

The unaudited pro forma information for the three and six months ended July 3, 2011 has been calculated after applying the Company's accounting policies and the impact of acquisition date fair value adjustments. The pro forma net income from continuing operations was adjusted to exclude nonrecurring expenses related to the fair value adjustments associated with the Caliper acquisition. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments, such as fair value adjustment to inventory and deferred revenue, increased interest expense on debt obtained to finance the transaction, and increased amortization for the fair value of acquired intangible assets. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities.

Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on revenue thresholds or product development milestones achieved through given dates, with changes in the fair value after the acquisition date affecting earnings to the extent the contingent consideration is to be settled in cash. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, or require acceleration of the amortization expense of definite-lived intangible assets.

In connection with the purchase price and related allocations for acquisitions, the Company estimates the fair value of deferred revenue assumed with its acquisitions. The estimated fair value of deferred revenue is determined by the legal performance obligation at the date of acquisition, and is generally based on the nature of the activities to be performed and the related costs to be incurred after the acquisition date. The fair value of an assumed liability related to deferred revenue is estimated based on the current market cost of fulfilling the obligation, plus a normal profit margin thereon. The estimated costs to fulfill the deferred revenue are based on the historical direct costs related to providing the services. The Company does not include any costs associated with selling effort, research and development, or the related fulfillment margins on these costs. In most acquisitions, profit associated with selling effort is excluded because the acquired businesses would have concluded the selling effort on the support contracts prior to the acquisition date. The estimated research and development costs are not included in the fair value determination, as these costs are not deemed to represent a legal obligation at the time of acquisition. The sum of the costs and operating income approximates, in theory, the amount that the Company would be required to pay a third-party to assume the obligation.

As of July 1, 2012, the purchase price and related allocation for the Caliper acquisition were preliminary. The preliminary allocation of the purchase price for the Caliper acquisition was based upon a preliminary valuation and the Company's estimates and assumptions underlying the preliminary valuation are subject to change within the measurement period (up to one year from the acquisition date). The primary areas of the preliminary purchase price allocation that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition date during the measurement period. During the measurement period, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of those assets and liabilities as of that date. Adjustments to the initial allocation of the purchase price during the measurement period require the revision of comparative prior period financial information when reissued in subsequent financial statements. The effect of measurement period adjustments to the allocation of the purchase price would be as if the adjustments had been completed on the acquisition date. The effects of measurement period adjustments may cause changes in depreciation, amortization, or other income or expense recognized in prior periods. All changes that do not qualify as measurement period adjustments are included in current period earnings. There were no changes made to the preliminary allocation during the three and six months ended July 1, 2012.

Total transaction costs related to acquisition activities for the three and six months ended July 1, 2012 were $0.1 million and $0.3 million, respectively. Total transaction costs related to acquisition activities for the three and six months ended July 3, 2011 were $1.1 million and $4.0 million, respectively. These transaction costs were expensed as incurred and recorded in selling, general and administrative expenses in the Company's condensed consolidated statements of operations.

Note 3: Discontinued Operations

As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. The Company has accounted for these businesses as discontinued operations and, accordingly, has presented the results of operations and related cash flows as discontinued operations for all periods presented. The assets and liabilities of these businesses have been presented separately, and are reflected within the assets and liabilities from discontinued operations in the accompanying condensed consolidated balance sheets as of July 1, 2012 and January 1, 2012.

The Company recorded the following gains and losses, which have been reported as gain (loss) on disposition of discontinued operations:



	Three Months Ended						Six Months Ended
	July 1, 2012			July 3, 2011			July 1, 2012		July 3, 2011
	(In thousands)
(Loss) gain on disposition of Illumination and Detection Solutions business	$	—		$	(111	)	$	16	$	(1,696	)
Gain (loss) on disposition of Photoflash business	485			(13		)	992		(9		)
(Loss) gain on disposition of other discontinued operations	(3		)	(33		)	9		(36		)
Gain (loss) on disposition of discontinued operations before income taxes	$	482		$	(157	)	$	1,017	$	(1,741	)

In November 2010, the Company sold its Illumination and Detection Solutions business, which was included in the Company’s Environmental Health segment, for $510.3 million, including an adjustment for net working capital. During the first six months of fiscal year 2011, the Company updated the net working capital adjustment associated with the sale of this business and other potential contingencies, which resulted in the recognition of a pre-tax loss of $1.7 million. This loss was recognized as loss on disposition of discontinued operations.

In December 2008, the Company’s management approved a plan to divest its Photoflash business within the Environmental Health segment. In June 2010, the Company sold the Photoflash business for $13.5 million, including an adjustment for net working capital, plus potential additional contingent consideration. During the first six months of fiscal year 2012, the Company recognized a pre-tax gain of $1.0 million for contingent consideration related to this sale. This gain was recognized as gain on disposition of discontinued operations.

The Company recorded tax provisions of $0.4 million and $0.5 million on disposition of discontinued operations for the three and six months ended July 1, 2012, respectively. The Company recorded tax benefits of $0.8 million and $0.02 million on disposition of discontinued operations for the three and six months ended July 3, 2011, respectively.

Note 4: Restructuring and Contract Termination Charges, Net

The Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, alignment with the Company’s growth strategy and the integration of its business units. The current portion of restructuring and contract termination charges, net, is recorded in accrued restructuring costs, and the long-term portion of restructuring and contract termination charges, net, is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring expenses and are included as a component of operating expenses from continuing operations.

A description of the restructuring plans and the activity recorded for the six months ended July 1, 2012 is listed below. Details of the plans initiated in previous years, particularly those listed under “Previous Restructuring and Integration Plans,” are discussed more fully in Note 4 to the audited consolidated financial statements in the 2011 Form 10-K.

The restructuring plans for the first and second quarters of fiscal year 2012 were intended principally to realign operations, research and development resources, and production resources as a result of recent acquisitions. The restructuring plans for the second and fourth quarters of fiscal year 2011 were intended principally to shift resources to higher growth geographic regions and end markets.

Q2 2012 Restructuring Plan

During the second quarter of fiscal year 2012, the Company’s management approved a plan to realign operations, research and development resources, and production resources as a result of recent acquisitions (the “Q2 2012 Plan”). As a result of the Q2 2012 Plan, and during the three months ended July 1, 2012, the Company recognized a $4.0 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. The Company expects to recognize an additional $5.4 million of incremental restructuring expense in future periods as services are provided for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, and will be recognized ratably over the future service period. As part of the Q2 2012 Plan, the Company will reduce headcount by 229 employees. All employees were notified of termination under the Q2 2012 Plan by July 1, 2012.

The following table summarizes the Q2 2012 Plan activity for the six months ended July 1, 2012:



	Severance
	(In thousands)
Provision	$	4,218
Amounts paid and foreign currency translation	(714		)
Balance at July 1, 2012	$	3,504

The Company anticipates that the remaining severance payments of $3.5 million for workforce reductions will be completed by the end of the fourth quarter of fiscal year 2013.

Q1 2012 Restructuring Plan

During the first quarter of fiscal year 2012, the Company’s management approved a plan to realign operations and production resources as a result of recent acquisitions (the “Q1 2012 Plan”). As a result of the Q1 2012 Plan, and during the six months ended July 1, 2012, the Company recognized a $5.4 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.8 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. The Company expects to recognize an additional $0.5 million of incremental restructuring expense in future periods as services are provided for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, and will be recognized ratably over the future service period. As part of the Q1 2012 Plan, the Company will reduce headcount by 129 employees. All employees were notified of termination and the Company completed all actions related to the closure of excess facility space under the Q1 2012 Plan by April 1, 2012.

The following table summarizes the Q1 2012 Plan activity for the six months ended July 1, 2012:



	Severance			Closure of Excess Facility Space			Total
	(In thousands)
Provision	$	6,125		$	79		$	6,204
Amounts paid and foreign currency translation	(3,236		)	(79		)	(3,315		)
Balance at July 1, 2012	$	2,889		$	—		$	2,889

The Company anticipates that the remaining severance payments of $2.9 million for workforce reductions will be completed by the end of the fourth quarter of fiscal year 2012.

Q4 2011 Restructuring Plan

During the fourth quarter of fiscal year 2011, the Company’s management approved a plan to shift resources to higher growth geographic regions and end markets (the “Q4 2011 Plan”). As a result of the Q4 2011 Plan, the Company recognized a $2.3 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities. The Company also recognized a $4.6 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. During the first six months of fiscal year 2012, the Company recorded a pre-tax restructuring reversal of $0.1 million relating to the Q4 2011 Plan due to a reduction in the estimated costs associated with the closure of an excess facility in the Environmental Health segment. As part of the Q4 2011 Plan, the Company reduced headcount by 114 employees. All employees were notified of termination and the Company completed all actions related to the closure of excess facility space under the Q4 2011 Plan by January 1, 2012.

The following table summarizes the Q4 2011 Plan activity for the six months ended July 1, 2012:



	Severance			Closure of Excess Facility Space			Total
	(In thousands)
Balance at January 1, 2012	$	4,674		$	370		$	5,044
Change in estimates	—			(135		)	(135		)
Amounts paid and foreign currency translation	(3,233		)	(60		)	(3,293		)
Balance at July 1, 2012	$	1,441		$	175		$	1,616

The Company anticipates that the remaining severance payments of $1.4 million for workforce reductions will be completed by the end of the second quarter of fiscal year 2013. The Company also anticipates that the remaining payments of $0.2 million for the closure of excess facility space will be paid through the third quarter of fiscal year 2012, in accordance with the terms of the applicable lease.

Q2 2011 Restructuring Plan

During the second quarter of fiscal year 2011, the Company’s management approved a plan to shift resources to higher growth geographic regions and end markets (the “Q2 2011 Plan”). As a result of the Q2 2011 Plan, the Company recognized a $2.2 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. The Company also recognized a $3.4 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. As part of the Q2 2011 Plan, the Company reduced headcount by 72 employees. All employees were notified of termination and the Company completed all actions related to the closure of excess facility space under the Q2 2011 Plan by July 3, 2011.

The following table summarizes the Q2 2011 Plan activity for the six months ended July 1, 2012:



	Severance			Closure of Excess Facility Space		Total
	(In thousands)
Balance at January 1, 2012	$	1,283		$	—	$	1,283
Amounts paid and foreign currency translation	(454		)	—		(454		)
Balance at July 1, 2012	$	829		$	—	$	829

The Company anticipates that the remaining severance payments of $0.8 million for workforce reductions will be completed by the end of the fourth quarter of fiscal year 2012.

Previous Restructuring and Integration Plans

The principal actions of the restructuring and integration plans from fiscal years 2001 through 2010 were workforce reductions related to the integration of the Company’s businesses in order to reduce costs and achieve operational efficiencies as well as workforce reductions in both the Human Health and Environmental Health segments by shifting resources into geographic regions and product lines that are more consistent with the Company’s growth strategy. During the six months ended July 1, 2012, the Company paid $2.5 million related to these plans and recorded an additional charge of $0.3 million to reduce the estimated sublease rental payments reasonably expected to be obtained for an excess facility in Europe within the Environmental Health segment, as well as a charge of $0.4 million related to higher than expected costs associated with workforce reductions in Europe within the Human Health segment. As of July 1, 2012, the Company had $12.7 million of remaining liabilities associated with these restructuring and integration plans, primarily for residual lease obligations related to closed facilities and remaining severance payments for workforce reductions in both the Human Health and Environmental Health segments. The Company expects to make payments for these leases, the terms of which vary in length, through fiscal year 2022.

Contract Termination Charges

The Company has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded a pre-tax charge of $0.4 million and made payments for these obligations of $0.8 million in the first six months of fiscal year 2012. The remaining balance of these accruals as of July 1, 2012 was $1.7 million.

Note 5: Interest and Other Expense, Net

Interest and other expense, net, consisted of the following:



	Three Months Ended						Six Months Ended
	July 1, 2012			July 3, 2011			July 1, 2012			July 3, 2011
	(In thousands)
Interest income	$	(150	)	$	(483	)	$	(360	)	$	(805	)
Interest expense	11,339			4,213			22,776			8,129
Other expense, net	169			541			1,772			2,703
Total interest and other expense, net	$	11,358		$	4,271		$	24,188		$	10,027

Note 6: Inventories, Net

Inventories as of July 1, 2012 and January 1, 2012 consisted of the following:



	July 1, 2012		January 1, 2012
	(In thousands)
Raw materials	$	76,954	$	72,913
Work in progress	12,522		14,656
Finished goods	154,960		153,194
Total inventories, net	$	244,436	$	240,763

Note 7: Income Taxes

The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority; and/or (iii) the statute of limitations expires regarding a tax position.

At July 1, 2012, the Company had gross tax effected unrecognized tax benefits of $47.8 million, of which $40.9 million, if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations.

At July 1, 2012, the Company had uncertain tax positions of $8.8 million, including accrued interest, net of tax benefits and penalties, which are expected to be resolved within the next year. A portion of the uncertain tax positions could affect the continuing operations effective tax rate depending on the ultimate resolution; however, the Company cannot quantify an estimated range at this time. The Company is subject to U.S. federal income tax as well as to income tax of numerous state and foreign jurisdictions.

Tax years ranging from 2003 through 2011 remain open to examination by various tax jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom, and the United States. The tax years under examination vary by jurisdiction.

As a result of the Caliper acquisition, the Company concluded that certain foreign operations did not require the same level of capital as previously expected, and therefore the Company plans to repatriate approximately $350.0 million of previously unremitted earnings and has provided for the estimated taxes on the repatriation of those earnings. As a result of the planned repatriation, the Company recorded an increase to the Company’s tax provision of $79.7 million in continuing operations in fiscal year 2011. The Company expects to utilize tax attributes, primarily those acquired in the Caliper acquisition, to minimize the cash taxes paid on the repatriation. As of July 1, 2012, the Company had completed the repatriation of $229.2 million of the $350.0 million of these previously unremitted earnings. The Company continues to maintain its permanent reinvestment assertion with regard to the remaining unremitted earnings of its foreign subsidiaries, and therefore does not accrue U.S. tax for the repatriation of its remaining unremitted foreign earnings.

Note 8: Debt

Senior Unsecured Revolving Credit Facility. On December 16, 2011, the Company entered into an amended and restated senior unsecured revolving credit facility. The agreement for the facility provides for $700.0 million of revolving loans and has an initial maturity of December 16, 2016. As of July 1, 2012, undrawn letters of credit in the aggregate amount of $12.0 million were treated as issued and outstanding under the senior unsecured revolving credit facility. The Company uses the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate at the time of borrowing plus a margin, or the base rate from time to time. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by Bank of America, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. The Eurocurrency margin as of July 1, 2012 was 130 basis points. The weighted average Eurocurrency interest rate as of July 1, 2012 was 0.24%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.54%. The Company had $264.0 million of borrowings in U.S. Dollars outstanding under the senior unsecured revolving credit facility as of July 1, 2012, with interest based on the above described Eurocurrency rate. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default customary for financings of this type and those contained in the Company's previous senior revolving credit agreement. The financial covenants in the Company's amended and restated senior unsecured revolving credit facility includes a debt-to-capital ratio, and two contingent covenants, a maximum consolidated leverage ratio and a minimum consolidated interest coverage ratio, applicable only if the Company's credit rating is downgraded below investment grade.

6% Senior Unsecured Notes due 2015. On May 30, 2008, the Company issued $150.0 million aggregate principal amount of senior unsecured notes due 2015 (the “2015 Notes”) in a private placement and received $150.0 million of proceeds from the issuance. The 2015 Notes mature in May 2015 and bear interest at an annual rate of 6%. Interest on the 2015 Notes is payable semi-annually on May 30th and November 30th each year. The Company may redeem some or all of the 2015 Notes at any time, at its option, at a make-whole redemption price plus accrued and unpaid interest. The indenture governing the 2015 Notes includes financial covenants of debt-to-capital ratios and a contingent multiple of total debt to earnings ratio, applicable only if the Company's credit rating is downgraded below investment grade.

5% Senior Unsecured Notes due 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due 2021 (the “2021 Notes”) in a registered public offering and received approximately $496.9 million of net proceeds from the issuance. The 2021 Notes were issued at 99.372% of the principal amount, which resulted in a discount of $3.1 million. The 2021 Notes mature in November 2021 and bear interest at an annual rate of 5%. Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes ) and a contemporaneous downgrade of the 2021 Notes below investment grade, each holder of 2021 Notes will have the right to require the Company to repurchase such holder's 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest.

Note 9: Earnings Per Share

Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations:



	Three Months Ended		Six Months Ended
	July 1, 2012	July 3, 2011	July 1, 2012	July 3, 2011
	(In thousands)
Number of common shares—basic	113,515	112,494	113,306	113,246
Effect of dilutive securities:
Stock options	824	995	825	1,007
Restricted stock awards	239	134	217	128
Number of common shares—diluted	114,578	113,623	114,348	114,381
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	1,457	714	1,482	1,318

Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Note 10: Industry Segment Information

The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The Company’s management reviews the results of the Company’s operations by the Human Health and Environmental Health operating segments. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2011 Form 10-K. The principal products and services of these operating segments are:


•	Human Health. Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets.


•	Environmental Health. Provides technologies and applications to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.

The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the expense related to mark-to-market and curtailments on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.

Revenue and operating income (loss) by operating segment, excluding discontinued operations, are shown in the table below:



	Three Months Ended						Six Months Ended
	July 1, 2012			July 3, 2011			July 1, 2012			July 3, 2011
	(In thousands)
Human Health
Product revenue	$	219,721		$	185,480		$	435,550		$	354,226
Service revenue	38,701			33,337			76,833			65,912
Total revenue	258,422			218,817			512,383			420,138
Operating income from continuing operations	31,538			28,446			53,483			49,983
Environmental Health
Product revenue	144,522			140,939			285,886			278,319
Service revenue	118,846			119,309			234,411			227,786
Total revenue	263,368			260,248			520,297			506,105
Operating income from continuing operations	28,159			21,748			54,554			51,990
Corporate
Operating loss from continuing operations⁽¹⁾	(9,910		)	(10,775		)	(21,868		)	(21,123		)
Continuing Operations
Product revenue	$	364,243		$	326,419		$	721,436		$	632,545
Service revenue	157,547			152,646			311,244			293,698
Total revenue	521,790			479,065			1,032,680			926,243
Operating income from continuing operations	49,787			39,419			86,169			80,850
Interest and other expense, net (see Note 5)	11,358			4,271			24,188			10,027
Income from continuing operations before income taxes	$	38,429		$	35,148		$	61,981		$	70,823

____________________________


⁽¹⁾	The expenses related to mark-to-market and curtailments on postretirement benefit plans have been included in the Corporate operating loss from continuing operations, and together constituted a pre-tax loss of $1.2 million and a pre-tax gain of $0.2 million for the six months ended July 1, 2012 and July 3, 2011, respectively.

Note 11: Stockholders’ Equity

Comprehensive Income:

The components of accumulated other comprehensive income consisted of the following:



	July 1, 2012			January 1, 2012
	(In thousands)
Foreign currency translation adjustments, net of income taxes	$	39,586		$	56,164
Unrecognized prior service costs, net of income taxes	2,169			2,169
Unrealized and realized losses on derivatives, net of income taxes	(3,490		)	(4,088		)
Unrealized net losses on securities, net of income taxes	(137		)	(159		)
Accumulated other comprehensive income	$	38,128		$	54,086

The tax effects on the foreign currency translation component of other comprehensive (loss) income have historically been minimal due to the Company’s position that undistributed earnings of foreign subsidiaries are indefinitely reinvested. During fiscal year 2011, as a result of the Caliper acquisition, the Company concluded that certain foreign operations did not require the same level of capital as previously expected, and therefore the Company plans to repatriate approximately $350.0 million of previously unremitted earnings and has provided for the estimated taxes on the repatriation of those earnings. Taxes have not been provided for unremitted earnings that the Company continues to consider indefinitely reinvested, which is based on its future operational and capital requirements.

During the fourth quarter of fiscal year 2011 the Company changed its method of recognizing defined benefit pension and other postretirement benefit costs. Accordingly, the financial data for all periods presented has been retrospectively adjusted to reflect the effect of these accounting changes. See Note 1 for a discussion of the Company's changes in accounting and reporting for its pension and other postretirement benefits.

Stock Repurchase Program:

On October 23, 2008, the Company announced that the Board of Directors (the “Board”) authorized the Company to repurchase up to 10.0 million shares of common stock under a stock repurchase program (the “Repurchase Program”). On August 31, 2010, the Company announced that the Board had authorized the Company to repurchase an additional 5.0 million shares of common stock under the Repurchase Program. The Repurchase Program will expire on October 22, 2012 unless terminated earlier by the Board, and may be suspended or discontinued at any time. During the first six months of fiscal year 2012, the Company did not repurchase any shares of common stock in the open market under the Repurchase Program. As of July 1, 2012, 6.0 million shares of the Company’s common stock remained available for repurchase from the 15.0 million shares authorized by the Board under the Repurchase Program.

The Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans. During the first six months of fiscal year 2012, the Company repurchased 80,690 shares of common stock for this purpose at an aggregate cost of $2.1 million. The repurchased shares have been reflected as a reduction in shares outstanding, but remain available to be reissued with the payments reflected in common stock and capital in excess of par value.

Dividends:

The Board declared a regular quarterly cash dividend of $0.07 per share in the first two quarters of fiscal year 2012 and in each quarter of fiscal year 2011. At July 1, 2012, the Company has accrued $8.0 million for dividends declared prior to quarter end. On July 27, 2012, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the second quarter of fiscal year 2012 that will be payable in November 2012. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Note 12: Stock Plans

The Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.0 million shares of the Company’s common stock, as well as shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were cancelled or forfeited without the shares being issued, are authorized for stock option grants, restricted stock awards, performance units and stock grants as part of the Company’s compensation programs (the “Plan”).

The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s condensed consolidated statements of operations for the three and six months ended July 1, 2012 and July 3, 2011:



	Three Months Ended				Six Months Ended
	July 1, 2012		July 3, 2011		July 1, 2012		July 3, 2011
	(In thousands)
Cost of revenue	$	304	$	246	$	580	$	506
Research and development expenses	185		149		361		295
Selling, general and administrative expenses	4,287		4,511		9,311		7,159
Total stock-based compensation expense	$	4,776	$	4,906	$	10,252	$	7,960

The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.5 million and $3.4 million for the three and six months ended July 1, 2012, respectively. The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.7 million and $2.7 million for the three and six months ended July 3, 2011, respectively. Stock-based compensation costs capitalized as part of inventory were $0.3 million and $0.2 million as of July 1, 2012 and July 3, 2011, respectively. The excess tax benefit recognized from stock awards, classified as a financing cash activity, was $1.1 million and $8.6 million for the six months ended July 1, 2012 and July 3, 2011, respectively.

Stock Options: The fair value of each option grant is estimated using the Black-Scholes option pricing model. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows:



	Three and Six Months Ended
	July 1, 2012		July 3, 2011
Risk-free interest rate	0.6	%	1.9	%
Expected dividend yield	1.2	%	1.1	%
Expected lives	4 years		4 years
Expected stock volatility	38.7	%	38.1	%

The following table summarizes stock option activity for the six months ended July 1, 2012:



	Number of Shares		Weighted- Average Price		Weighted-Average Remaining Contractual Term	Total Intrinsic Value
	(In thousands)				(In years)	(In millions)
Outstanding at January 1, 2012	5,346		$	20.57
Granted	740		26.25
Exercised	(637	)	18.44
Canceled	(206	)	22.26
Forfeited	(5	)	14.76
Outstanding at July 1, 2012	5,238		$	21.57	3.8	$	25.8
Exercisable at July 1, 2012	3,633		$	20.34	2.8	$	22.3
Vested and expected to vest in the future	4,783		$	21.57	3.8	$	23.5

The weighted-average per-share grant-date fair value of options granted for the three and six months ended July 1, 2012 was $7.73 and $7.35, respectively. The weighted-average per-share grant-date fair value of options granted for the three and six months ended July 3, 2011 was $8.29 and $7.86, respectively. The total intrinsic value of options exercised for the three and six months ended July 1, 2012 was $0.9 million and $5.2 million, respectively. The total intrinsic value of options exercised for the three and six months ended July 3, 2011 was $1.8 million and $6.9 million, respectively. Cash received from option exercises for the six months ended July 1, 2012 and July 3, 2011 was $11.7 million and $23.6 million, respectively.

The total compensation expense recognized related to the Company’s outstanding options was $1.3 million and $2.5 million for the three and six months ended July 1, 2012, respectively, and $1.1 million and $2.2 million for the three and six months ended July 3, 2011, respectively.

There was $8.8 million of total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock options granted as of July 1, 2012. This cost is expected to be recognized over a weighted-average period of 2.2 fiscal years and will be adjusted for any future changes in estimated forfeitures.

Restricted Stock Awards: The following table summarizes restricted stock award activity for the six months ended July 1, 2012:



	Number of Shares		Weighted- Average Grant- Date Fair Value
	(In thousands)
Nonvested at January 1, 2012	672		$	23.62
Granted	351		25.83
Vested	(179	)	23.27
Forfeited	(19	)	25.26
Nonvested at July 1, 2012	825		$	24.60

The weighted-average per-share grant-date fair value of restricted stock awards granted during the three and six months ended July 1, 2012 was $25.55 and $25.83, respectively. The weighted-average per-share grant-date fair value of restricted stock awards granted during the three and six months ended July 3, 2011 was $27.81 and $26.77, respectively. The fair value of restricted stock awards vested for the three and six months ended July 1, 2012 was $1.3 million and $4.2 million, respectively. The fair value of restricted stock awards vested for the three and six months ended July 3, 2011 was $2.4 million and $5.3 million, respectively. The total compensation expense recognized related to the Company’s outstanding restricted stock awards was $2.2 million and $4.1 million for the three and six months ended July 1, 2012, respectively, and $1.6 million and $3.0 million for the three and six months ended July 3, 2011, respectively.

As of July 1, 2012, there was $13.8 million of total unrecognized compensation cost, net of forfeitures, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.7 fiscal years.

Performance Units: The Company granted 122,675 performance units and 89,828 performance units during the six months ended July 1, 2012 and July 3, 2011, respectively, as part of the Company’s executive incentive program. The weighted-average per-share grant-date fair value of performance units granted during the six months ended July 1, 2012 and July 3, 2011 was $26.18 and $26.71, respectively. The total compensation expense recognized related to these performance units was $0.6 million and $2.8 million for the three and six months ended July 1, 2012, respectively, and $1.4 million and $1.9 million for the three and six months ended July 3, 2011, respectively. As of July 1, 2012, there were 322,516 performance units outstanding and subject to forfeiture, with a corresponding liability of $6.3 million recorded in accrued expenses.

Stock Awards: The Company generally grants stock awards only to non-employee members of the Board. The Company granted 4,535 shares and 3,544 shares to each non-employee member of the Board during the six months ended July 1, 2012 and July 3, 2011, respectively. The weighted-average per-share grant-date fair value of stock awards granted during the six months ended July 1, 2012 and July 3, 2011 was $27.87 and $28.22, respectively. The total compensation expense recognized related to these stock awards was $0.7 million for each of the three and six months ended July 1, 2012, and $0.8 million for each of the three and six months ended July 3, 2011.

Employee Stock Purchase Plan: During the six months ended July 1, 2012, the Company issued 53,961 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $24.51 per share. At July 1, 2012, an aggregate of 1.2 million shares of the Company’s common stock remained available for sale to employees out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Note 13: Goodwill and Intangible Assets, Net

The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets.

The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. The Company performed its annual impairment testing for its reporting units as of January 2, 2012, its annual impairment date for fiscal year 2012, and concluded based on the first step of the process that there was no goodwill impairment.

The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rate and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The long-term terminal growth rates for the Company’s reporting units ranged from 4.0% to 6.0% for the fiscal year 2012 impairment analysis. The range for the discount rates for the reporting units was 10.5% to 12.0%. Keeping all other variables constant, a 10.0% change in any one of the input assumptions for the various reporting units would still allow the Company to conclude, based on the first step of the process, that there was no impairment of goodwill.

The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company currently evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 2, 2012, and concluded that there was no impairment of non-amortizing intangible assets. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during the first six months of fiscal year 2012.

The changes in the carrying amount of goodwill for the period ended July 1, 2012 from January 1, 2012 were as follows:



	Human Health			Environmental Health			Consolidated
	(In thousands)
Balance at January 1, 2012	$	1,390,571		$	703,055		$	2,093,626
Foreign currency translation	(9,028		)	(4,567		)	(13,595		)
Balance at July 1, 2012	$	1,381,543		$	698,488		$	2,080,031

Identifiable intangible asset balances at July 1, 2012 and January 1, 2012 by category were as follows:



	July 1, 2012			January 1, 2012
	(In thousands)
Patents	$	107,571		$	107,437
Less: Accumulated amortization	(87,852		)	(85,188		)
Net patents	19,719			22,249
Trade names and trademarks	34,034			35,214
Less: Accumulated amortization	(12,075		)	(11,086		)
Net trade names and trademarks	21,959			24,128
Licenses	79,573			79,873
Less: Accumulated amortization	(42,211		)	(37,339		)
Net licenses	37,362			42,534
Core technology	385,338			385,112
Less: Accumulated amortization	(229,912		)	(212,834		)
Net core technology	155,426			172,278
Customer relationships	314,711			316,782
Less: Accumulated amortization	(89,078		)	(69,710		)
Net customer relationships	225,633			247,072
IPR&D	7,026			7,131
Less: Accumulated amortization	(1,150		)	(819		)
Net IPR&D	5,876			6,312
Net amortizable intangible assets	465,975			514,573
Non-amortizing intangible assets:
Trade names and trademarks	147,034			147,034
Totals	$	613,009		$	661,607

Total amortization expense related to definite-lived intangible assets for the six months ended July 1, 2012 and July 3, 2011 was $46.7 million and $35.7 million, respectively. Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $42.6 million for the remainder of fiscal year 2012, $85.5 million for fiscal year 2013, $77.7 million for fiscal year 2014, $62.9 million for fiscal year 2015, and $52.3 million for fiscal year 2016.

Note 14: Warranty Reserves

The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses” on the condensed consolidated balance sheets. Warranty reserve activity for the three and six months ended July 1, 2012 and July 3, 2011 is summarized below:



	Three Months Ended						Six Months Ended
	July 1, 2012			July 3, 2011			July 1, 2012			July 3, 2011
	(In thousands)
Balance beginning of period	$	10,749		$	8,271		$	10,412		$	8,250
Provision charged to income	4,271			3,731			8,897			7,059
Payments	(4,193		)	(3,735		)	(9,040		)	(7,162		)
Adjustments to previously provided warranties, net	30			682			487			557
Foreign currency translation and acquisitions	(232		)	108			(131		)	353
Balance end of period	$	10,625		$	9,057		$	10,625		$	9,057

Note 15: Employee Postretirement Benefit Plans

The following table summarizes the components of net periodic benefit cost (credit) for the Company’s various defined benefit employee pension and postretirement plans for the three and six months ended July 1, 2012 and July 3, 2011:



	Defined Benefit Pension Benefits						Postretirement Medical Benefits
	Three Months Ended
	July 1, 2012			July 3, 2011			July 1, 2012			July 3, 2011
	(In thousands)
Service cost	$	977		$	972		$	28		$	21
Interest cost	5,792			6,321			37			41
Expected return on plan assets	(5,140		)	(5,649		)	(219		)	(221		)
Amortization of prior service costs	(60		)	(56		)	—			(63		)
Net periodic benefit cost (credit)	$	1,569		$	1,588		$	(154	)	$	(222	)

	Defined Benefit Pension Benefits						Postretirement Medical Benefits
	Six Months Ended
	July 1, 2012			July 3, 2011			July 1, 2012			July 3, 2011
	(In thousands)
Service cost	$	1,957		$	1,944		$	56		$	43
Interest cost	11,607			12,639			74			81
Expected return on plan assets	(10,282		)	(11,297		)	(438		)	(442		)
Amortization of prior service	(120		)	(112		)	—			(126		)
Net periodic benefit cost (credit)	$	3,162		$	3,174		$	(308	)	$	(444	)

During the first six months of fiscal year 2012, the Company made a contribution of $17.0 million for the 2011 plan year to its defined benefit pension plan in the United States. During the first six months of fiscal year 2012, the Company made contributions of $5.5 million in the aggregate to its defined benefit pension plans outside of the United States.

Note 16: Derivatives and Hedging Activities

The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. The fluctuations in foreign currency can increase the costs of financing, investing and operating the business. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures.

In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. Unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in earnings for hedges designated as fair value and, for hedges designated as cash flow, the related unrealized gains or losses are deferred as a component of other comprehensive (loss) income in the accompanying condensed consolidated balance sheets. Deferred gains and losses are recognized in income in the period in which the underlying anticipated transaction occurs and impacts earnings.

Principal hedged currencies include the British Pound, Canadian Dollar, Euro, Japanese Yen and Singapore Dollar. The Company held forward foreign exchange contracts with U.S. equivalent notional amounts totaling $61.7 million at July 1, 2012 and $108.4 million at July 3, 2011, and the approximate fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days during both fiscal years 2012 and 2011. Also, during the six months ended July 1, 2012 the Company entered into two forward foreign exchange contracts with the same institution and having the same settlement date in October 2012, with Euro denominated notional amounts of Euro 125.0 million. The fair value of these currency derivative contracts at July 1, 2012 was a net receivable of $4.1 million.

In May 2008, the Company settled forward interest rate contracts with notional amounts totaling $150.0 million upon the issuance of its 2015 Notes, and recognized $8.4 million, net of taxes of $5.4 million, of accumulated derivative losses in other comprehensive (loss) income. The derivative losses are being amortized into interest expense when the hedged exposure affects interest expense. As of July 1, 2012, the balance remaining in accumulated other comprehensive income related to the effective cash flow hedges was $3.5 million, net of taxes of $2.3 million. The Company amortized into interest expense $1.0 million for the first six months of fiscal year 2012 and $2.0 million for fiscal year 2011.

Note 17: Fair Value Measurements

The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the six months ended July 1, 2012. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition-related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.

Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

The following tables show the assets and liabilities carried at fair value measured on a recurring basis at July 1, 2012 and January 1, 2012 classified in one of the three classifications described above:



	Fair Value Measurements at July 1, 2012 Using:
	Total Carrying Value at July 1, 2012			Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
	(In thousands)
Marketable securities	$	1,102		$	1,102	$	—		$	—
Foreign exchange derivative assets, net	4,050			—		4,050			—
Foreign exchange derivative liabilities, net	(41		)	—		(41		)	—
Contingent consideration	(7,315		)	—		—			(7,315		)



	Fair Value Measurements at January 1, 2012 Using:
	Total Carrying Value at January 1, 2012			Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
	(In thousands)
Marketable securities	$	1,105		$	1,105	$	—		$	—
Foreign exchange derivative liabilities, net	(213		)	—		(213		)	—
Contingent consideration	(20,298		)	—		—			(20,298		)

Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities.



Marketable securities	Include equity and fixed-income securities measured at fair value using the quoted market prices at the reporting date.
Foreign exchange derivative assets and liabilities	Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date.

The Company has classified its net liabilities for contingent consideration relating to its acquisitions of chemagen Biopolymer-Technologie AG, ArtusLabs, Inc., ID Biological Systems, Inc., and Dexela Limited within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included probability weighted cash flows. A description of the acquisitions is included within Note 2 to the Company's audited consolidated financial statements filed with the 2011 Form 10-K. Contingent consideration is measured at fair value at the acquisition date, based on revenue thresholds or product development milestones anticipated to be achieved during the earnout period. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration of up to $24.3 million, with an estimated fair value of $7.3 million at July 1, 2012. The earnouts periods for these acquisitions do not exceed three years from acquisition. A reconciliation of the beginning and ending Level 3 net liabilities is as follows:



	Three Months Ended						Six Months Ended
	July 1, 2012			July 3, 2011			July 1, 2012			July 3, 2011
	(In thousands)
Balance beginning of period	$	(20,636	)	$	(15,645	)	$	(20,298	)	$	(1,731	)
Additions	—			(4,600		)	—			(20,131		)
Amounts paid and foreign currency translation	13,646			—			13,646			1,908
Change in fair value (included within selling, general and administrative expenses)	(325		)	(664		)	(663		)	(955		)
Balance end of period	$	(7,315	)	$	(20,909	)	$	(7,315	)	$	(20,909	)

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.

The Company’s senior unsecured revolving credit facility, with a $700.0 million available limit, had carrying values of $264.0 million and $298.0 million as of July 1, 2012 and January 1, 2012, respectively. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during the first six months of fiscal year 2012. Consequently, the carrying value of the current year and prior year credit facilities approximate fair value and would be classified as Level 2.

The Company’s 2015 Notes, with a face value of $150.0 million, had an aggregate carrying value of $150.0 million and a fair value of $163.5 million as of July 1, 2012. The 2015 Notes had an aggregate carrying value of $150.0 million and a fair value of $165.7 million as of January 1, 2012. The Company's 2021 Notes, with a face value of $500.0 million, had an aggregate carrying value of $497.0 million, net of $3.0 million of unamortized original issue discount, and a fair value of $523.8 million as of July 1, 2012. The 2021 Notes had an aggregate carrying value of $496.9 million, net of $3.1 million of unamortized original issue discount, and a fair value of $518.3 million as of January 1, 2012. The fair values of the 2015 Notes and the 2021 Notes are estimated using market quotes from brokers, or are based on current rates offered for similar debt. As of July 1, 2012, long-term debt was classified as Level 2.

As of July 1, 2012, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Note 18: Contingencies

The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $5.5 million as of July 1, 2012, which represents management’s estimate of the total cost of ultimate disposition of known environmental matters. This amount is not discounted and does not reflect the recovery of any amounts through insurance or indemnification arrangements. These cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded.

Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”) filed a complaint dated October 23, 2002 in the United States District Court for the Southern District of New York, Civil Action No. 02-8448, against Amersham plc, Amersham BioSciences, PerkinElmer, Inc., PerkinElmer Life Sciences, Inc., Sigma-Aldrich Corporation, Sigma Chemical Company, Inc., Molecular Probes, Inc., and Orchid BioSciences, Inc. (the “New York Case”). The complaint alleges that the Company has breached its distributorship and settlement agreements with Enzo, infringed Enzo’s patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo’s patented products and technology, separately and together with the other defendants. Enzo seeks injunctive and monetary relief. In 2003, the court severed the lawsuit and ordered Enzo to serve individual complaints against the five defendants. The Company subsequently filed an answer and a counterclaim alleging that Enzo’s patents are invalid. In July 2006, the court issued a decision regarding the construction of the claims in Enzo’s patents that effectively limited the coverage of certain of those claims and, the Company believes, excludes certain of the Company’s products from the coverage of Enzo’s patents. Summary judgment motions were filed by the defendants in January 2007, and a hearing with oral argument on those motions took place in July 2007. In January 2009, the case was assigned to a new district court judge and in March 2009, the new judge denied the pending summary judgment motions without prejudice and ordered a stay of the case until the federal appellate court decides Enzo’s appeal of the judgment of the United States District Court for the District of Connecticut in Enzo Biochem vs. Applera Corp. and Tropix, Inc. (the “Connecticut Case”), which involves a number of the same patents and which could materially affect the scope of Enzo’s case against the Company. On March 26, 2010, the United States Court of Appeals for the Federal Circuit affirmed-in-part and reversed-in-part the judgment in the Connecticut Case. The New York Case against the Company and other defendants remains stayed except that the district court has permitted the Company and the other defendants to jointly file a motion for summary judgment on certain patent and other issues common to all of the defendants.

The Company believes it has meritorious defenses to the matter described above, and it is contesting the action vigorously. While this matter is subject to uncertainty, in the opinion of the Company’s management, based on its review of the information available at this time, the resolution of this matter will not have a material adverse effect on the Company’s condensed consolidated financial statements.

The Company is also subject to various other claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these other contingencies at July 1, 2012 should not have a material adverse effect on the Company’s condensed consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Table of Contents


Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations

This quarterly report on Form 10-Q, including the following management’s discussion and analysis, contains forward-looking information that you should read in conjunction with the condensed consolidated financial statements and notes to the condensed consolidated financial statements that we have included elsewhere in this report. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “plans,” “anticipates,” “intends,” “expects,” “will” and similar expressions are intended to identify forward-looking statements. Our actual results may differ materially from the plans, intentions or expectations we disclose in the forward-looking statements we make. We have included important factors below under the heading “Risk Factors” in Part II, Item 1A. that we believe could cause actual results to differ materially from the forward-looking statements we make. We are not obligated to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Overview

We are a leading provider of technology, services and solutions to the diagnostics, research, environmental and safety, industrial and laboratory services markets. Through our advanced technologies, solutions and services, we address critical issues that help to improve the health and safety of people and their environment in two reporting segments:


•	Human Health. Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets.


•	Environmental Health. Provides technologies and applications to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.

Overview of the Second Quarter of Fiscal Year 2012

Our fiscal year ends on the Sunday nearest December 31. We report fiscal years under a 52/53 week format, and as a result certain fiscal years will contain 53 weeks. Both our 2012 and 2011 fiscal years include 52 weeks.

During the second quarter of fiscal year 2012, we continued to see good performance from acquisitions, investments in our ongoing technology and sales and marketing initiatives. Our overall revenue in the second quarter of fiscal year 2012 increased $42.7 million, or 9%, as compared to the second quarter of fiscal year 2011, reflecting an increase of $39.6 million, or 18%, in our Human Health segment revenue and an increase of $3.1 million, or 1%, in our Environmental Health segment revenue. The increase in our Human Health segment revenue during the three months ended July 1, 2012 was due to growth generated from both our screening and our medical imaging businesses within the diagnostics market, as well as the addition of Caliper Life Sciences, Inc. ("Caliper") within the research market. The increase in our Environmental Health segment revenue during the three months ended July 1, 2012 was due to growth in our informatics offerings within the laboratory services market and growth from our environmental, food and consumer safety and testing products, partially offset by decreased demand for our applications in the industrial markets.

In our Human Health segment during the second quarter of fiscal year 2012 as compared to the second quarter of fiscal year 2011, we experienced growth in the diagnostics market as birth rates in the United States begin to stabilize and from continued expansion of our prenatal, newborn and infectious disease screening solutions in key regions outside the United States, particularly in emerging markets such as China. In our medical imaging business, we had continued growth from our traditional diagnostic imaging offerings, as well as increased demand for our complementary metal-oxide-semiconductor (“CMOS”) imaging technology, which was primarily focused on surgical applications. We also experienced growth in the research market due to continued demand for our in-vivo imaging systems with the addition of Caliper imaging systems. The growth in the research market was partially offset by reduced sales to pharmaceutical companies resulting from reduced research and development spending, as well as a decline in demand for our suite of radiometric detection equipment and reagents, particularly in Europe. As the rising cost of healthcare continues to be one of the critical issues facing our customers, we anticipate that even with continued pressure on laboratory budgets and credit availability, the benefits of providing earlier detection of disease, which can result in savings of long-term health care costs as well as creating better outcomes for patients, are increasingly valued and we expect to see continued growth in these markets.

In our Environmental Health segment, our laboratory services business offers services designed to enable our customers to increase efficiencies and production time, while reducing maintenance costs, all of which continue to be critical for our customers. During the second quarter of fiscal year 2012, we had increased demand for our informatics offerings, and we continued to grow our laboratory services business by adding new customers to our OneSource multivendor service offering. Sales of environmental, food and consumer safety and testing products grew in the second quarter of fiscal year 2012, as

Table of Contents

compared to the second quarter of fiscal year 2011 as increased regulations in environmental and food safety markets continued to drive demand for our analytical instrumentation and follow-on consumables, particularly in China and South America. We saw continued strength in our inorganic analysis solutions, such as our NexION^® mass spectrometer, as trace metals identification remains a critical component of contaminant detection for environmental, as well as food and consumer safety, applications. These increases were partially offset by decreased demand for our applications in the industrial markets. We believe these trends will continue as emerging contaminant testing protocols and corresponding regulations are developed, resulting in continued demand for efficient, analytically sensitive and information rich testing solutions.

Our consolidated gross margins increased 210 basis points in the second quarter of fiscal year 2012, as compared to the second quarter of fiscal year 2011, due to increased sales volume, changes in product mix with growth in sales of higher gross margin product offerings and productivity improvements. Our consolidated operating margin increased 131 basis points in the second quarter of fiscal year 2012, as compared to the second quarter of fiscal year 2011, primarily as a result of higher gross margins, cost containment and productivity initiatives, partially offset by increased costs related to acquisitions and growth investments in research and development.

We believe we are well positioned to continue to take advantage of the stable spending trends in our end markets and to promote our efficiencies in markets where current conditions may increase demand for certain services. Overall, we believe that our strategic focus on Human Health and Environmental Health coupled with our breadth of end markets, deep portfolio of technologies and applications, leading market positions, global scale and financial strength will provide us with a strong foundation for continued growth.

Critical Accounting Policies and Estimates

The preparation of condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, sales and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, warranty costs, bad debts, inventories, accounting for business combinations and dispositions, long-lived assets, income taxes, restructuring, pensions and other postretirement benefits, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Critical accounting policies are those policies that affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements. We believe our critical accounting policies include our policies regarding revenue recognition, warranty costs, allowances for doubtful accounts, inventory valuation, business combinations, value of long-lived assets, including goodwill and other intangibles, employee compensation and benefits, restructuring activities, gains or losses on dispositions and income taxes.

For a more detailed discussion of our critical accounting policies and estimates, please refer to the Notes to our Audited Consolidated Financial Statements and Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the fiscal year ended January 1, 2012 (our “2011 Form 10-K”), as filed with the Securities and Exchange Commission.

Consolidated Results of Continuing Operations

Revenue

Revenue for the three months ended July 1, 2012 was $521.8 million, as compared to $479.1 million for the three months ended July 3, 2011, an increase of $42.7 million, or 9%, which includes an approximate 4% decrease in revenue attributable to unfavorable changes in foreign exchange rates and an approximate 8% increase from acquisitions. The analysis in the remainder of this paragraph compares segment revenue for the three months ended July 1, 2012 as compared to the three months ended July 3, 2011 and includes the effect of foreign exchange rate fluctuations and acquisitions. The total increase in revenue reflects an increase of $39.6 million, or 18%, in our Human Health segment revenue due to an increase in research market revenue of $24.5 million and an increase in diagnostics market revenue of $15.1 million. Our Environmental Health segment revenue increased $3.1 million, or 1%, due to an increase in laboratory services market revenue of $6.3 million, partially offset by decreases in environmental and safety and industrial markets revenue of $3.2 million. As a result of adjustments to deferred revenue related to certain acquisitions required by business combination rules, we did not recognize $10.5 million of revenue for the three months ended July 1, 2012 and $6.2 million for the three months ended July 3, 2011 that otherwise would have been recorded by the acquired businesses during each of the respective periods.

Table of Contents

Revenue for the six months ended July 1, 2012 was $1,032.7 million, as compared to $926.2 million for the six months ended July 3, 2011, an increase of $106.4 million, or 11%, which includes an approximate 3% decrease in revenue attributable to unfavorable changes in foreign exchange rates and an approximate 9% increase from acquisitions. The analysis in the remainder of this paragraph compares segment revenue for the six months ended July 1, 2012 as compared to the six months ended July 3, 2011 and includes the effect of foreign exchange rate fluctuations and acquisitions. The total increase in revenue reflects an increase of $92.2 million, or 22%, in our Human Health segment revenue due to an increase in research market revenue of $60.8 million, and an increase in diagnostics market revenue of $31.4 million. Our Environmental Health segment revenue increased $14.2 million, or 3%, due to an increase in laboratory services market revenue of $15.6 million, offset by decreases in environmental and safety and industrial markets revenue of $1.4 million. As a result of adjustments to deferred revenue related to certain acquisitions required by business combination rules, we did not recognize $16.9 million of revenue for the six months ended July 1, 2012 and $6.4 million for the six months ended July 3, 2011 that otherwise would have been recorded by the acquired businesses during each of the respective periods.

Cost of Revenue

Cost of revenue for the three months ended July 1, 2012 was $283.0 million, as compared to $269.9 million for the three months ended July 3, 2011, an increase of $13.1 million, or 5%. As a percentage of revenue, cost of revenue decreased to 54.2% for the three months ended July 1, 2012, from 56.3% for the three months ended July 3, 2011, resulting in an increase in gross margin of 210 basis points to 45.8% for the three months ended July 1, 2012, from 43.7% for the three months ended July 3, 2011. Amortization of intangible assets decreased and was $12.9 million for the three months ended July 1, 2012, as compared to $13.4 million for the three months ended July 3, 2011. Stock-based compensation expense increased and was $0.3 million for the three months ended July 1, 2012, as compared to $0.2 million for the three months ended July 3, 2011. The amortization of purchase accounting adjustments to record the inventory from certain acquisitions completed in fiscal year 2011 was $0.3 million for each of the three months ended July 1, 2012 and July 3, 2011. The increase in gross margin was primarily the result of increased sales volume, changes in product mix with growth in sales of higher gross margin product offerings and productivity improvements.

Cost of revenue for the six months ended July 1, 2012 was $561.9 million, as compared to $516.7 million for the six months ended July 3, 2011, an increase of $45.1 million, or 9%. As a percentage of revenue, cost of revenue decreased to 54.4% for the six months ended July 1, 2012, from 55.8% for the six months ended July 3, 2011, resulting in a increase in gross margin of 138 basis points to 45.6% for the six months ended July 1, 2012, from 44.2% for the six months ended July 3, 2011. Amortization of intangible assets increased and was $25.9 million for the six months ended July 1, 2012, as compared to $24.8 million for the six months ended July 3, 2011. Stock-based compensation expense increased and was $0.6 million for the six months ended July 1, 2012, as compared to $0.5 million for the six months ended July 3, 2011. The amortization of purchase accounting adjustments to record the inventory from certain acquisitions completed in fiscal year 2011 was $4.8 million for the six months ended July 1, 2012, as compared to $0.4 million for the six months ended July 3, 2011. The increase in gross margin was primarily the result of increased sales volume, changes in product mix with growth in sales of higher gross margin product offerings and productivity improvements, partially offset by increased costs related to acquisitions.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended July 1, 2012 were $149.7 million, as compared to $138.4 million for the three months ended July 3, 2011, an increase of $11.3 million, or 8%. As a percentage of revenue, selling, general and administrative expenses decreased and were 28.7% for the three months ended July 1, 2012, as compared to 28.9% for the three months ended July 3, 2011. Amortization of intangible assets increased and was $10.1 million for the three months ended July 1, 2012, as compared to $5.7 million for the three months ended July 3, 2011. Stock-based compensation expense decreased and was $4.3 million for the three months ended July 1, 2012, as compared to $4.5 million for the three months ended July 3, 2011. Acquisition related costs for integration, contingent consideration and other acquisition costs related to certain acquisitions was an expense of $0.7 million for the three months ended July 1, 2012, as compared to $1.8 million for the three months ended July 3, 2011. The increase in selling, general and administrative expenses was primarily the result of costs related to acquisitions, partially offset by cost containment and productivity initiatives.

Selling, general and administrative expenses for the six months ended July 1, 2012 were $306.6 million, as compared to $271.1 million for the six months ended July 3, 2011, an increase of $35.5 million, or 13%. As a percentage of revenue, selling, general and administrative expenses increased and were 29.7% for the six months ended July 1, 2012, as compared to 29.3% for the six months ended July 3, 2011. Amortization of intangible assets increased and was $20.4 million for the six months ended July 1, 2012, as compared to $10.3 million for the six months ended July 3, 2011. Stock-based compensation expense increased and was $9.3 million for the six months ended July 1, 2012, as compared to $7.2 million for the six months ended July 3, 2011. Acquisition related costs for integration, contingent consideration and other acquisition costs related to certain acquisitions was an expense of $1.5 million for the six months ended July 1, 2012, as compared to $5.0 million for the six

Table of Contents

months ended July 3, 2011. The increase in selling, general and administrative expenses was primarily the result of costs related to acquisitions and increased sales and marketing expenses, particularly in emerging territories, partially offset by cost containment and productivity initiatives.

Research and Development Expenses

Research and development expenses for the three months ended July 1, 2012 were $34.1 million, as compared to $28.0 million for the three months ended July 3, 2011, an increase of $6.0 million, or 22%. As a percentage of revenue, research and development expenses increased and were 6.5% for the three months ended July 1, 2012, as compared to 5.9% for the three months ended July 3, 2011. Amortization of intangible assets increased and was $0.3 million for the three months ended July 1, 2012, as compared to $0.2 million for the three months ended July 3, 2011. Stock-based compensation expense increased and was $0.2 million for the three months ended July 1, 2012, as compared to $0.1 million for the three months ended July 3, 2011. We primarily directed research and development efforts during fiscal years 2012 and 2011 toward the diagnostics and research markets within our Human Health segment, and the environmental, and laboratory service and support markets within our Environmental Health segment, in order to help accelerate our growth initiatives.

Research and development expenses for the six months ended July 1, 2012 were $66.7 million, as compared to $54.2 million for the six months ended July 3, 2011, an increase of $12.5 million, or 23%. As a percentage of revenue, research and development expenses increased and were 6.5% for the six months ended July 1, 2012, as compared to 5.9% for the six months ended July 3, 2011. Amortization of intangible assets decreased and was $0.4 million for the six months ended July 1, 2012, as compared to $0.5 million for the six months ended July 3, 2011. Stock-based compensation expense increased and was $0.4 million for the six months ended July 1, 2012, as compared to $0.3 million for the six months ended July 3, 2011.

Restructuring and Contract Termination Charges, Net

We have undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, alignment with our growth strategy and the integration of our business units. The current portion of restructuring and contract termination charges, net, is recorded in accrued restructuring costs, and the long-term portion of restructuring and contract termination charges, net, is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring expenses and are included as a component of operating expenses from continuing operations.

The restructuring plans for the first and second quarters of fiscal year 2012 were intended principally to realign operations, research and development resources, and production resources as a result of recent acquisitions. We expect the impact of immediate cost savings from the restructuring plans on operating results and cash flows to approximately offset the increased spending required to realign operations. We expect the impact of future cost savings from these restructuring activities on operating results and cash flows will exceed $10.0 million on an annual basis beginning in fiscal year 2014, primarily as a decrease to cost of revenue and a decrease to selling, general and administrative expenses.

The restructuring plans for the second and fourth quarters of fiscal year 2011 were intended principally to shift resources to higher growth geographic regions and end markets. We expect the impact of immediate cost savings from the restructuring plans on operating results and cash flows to approximately offset the increased spending required in higher growth geographic regions. We expect the impact of future cost savings from these restructuring activities on operating results and cash flows to be negligible, as we will incur offsetting costs by shifting such resources.

Q2 2012 Restructuring Plan

During the second quarter of fiscal year 2012, our management approved a plan to realign operations, research and development resources, and production resources as a result of recent acquisitions (the “Q2 2012 Plan”). As a result of the Q2 2012 Plan, and during the three months ended July 1, 2012, we recognized a $4.0 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. We expect to recognize an additional $5.4 million of incremental restructuring expense in future periods as services are provided for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, and will be recognized ratably over the future service period. As part of the Q2 2012 Plan, we will reduce headcount by 229 employees. All employees were notified of termination under the Q2 2012 Plan by July 1, 2012.

Table of Contents

The following table summarizes the Q2 2012 Plan activity for the six months ended July 1, 2012:



	Severance
	(In thousands)
Provision	$	4,218
Amounts paid and foreign currency translation	(714		)
Balance at July 1, 2012	$	3,504

We anticipate that the remaining severance payments of $3.5 million for workforce reductions will be completed by the end of the fourth quarter of fiscal year 2013.

Q1 2012 Restructuring Plan

During the first quarter of fiscal year 2012, our management approved a plan to realign operations and production resources as a result of recent acquisitions (the “Q1 2012 Plan”). As a result of the Q1 2012 Plan, and during the six months ended July 1, 2012, we recognized a $5.4 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.8 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. We expect to recognize an additional $0.5 million of incremental restructuring expense in future periods as services are provided for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, and will be recognized ratably over the future service period. As part of the Q1 2012 Plan, we will reduce headcount by 129 employees. All employees were notified of termination and we completed all actions related to the closure of excess facility space under the Q1 2012 Plan by April 1, 2012.

The following table summarizes the Q1 2012 Plan activity for the six months ended July 1, 2012:



	Severance			Closure of Excess Facility Space			Total
	(In thousands)
Provision	$	6,125		$	79		$	6,204
Amounts paid and foreign currency translation	(3,236		)	(79		)	(3,315		)
Balance at July 1, 2012	$	2,889		$	—		$	2,889

We anticipate that the remaining severance payments of $2.9 million for workforce reductions will be completed by the end of the fourth quarter of fiscal year 2012.

Q4 2011 Restructuring Plan

During the fourth quarter of fiscal year 2011, our management approved a plan to shift resources to higher growth geographic regions and end markets (the “Q4 2011 Plan”). As a result of the Q4 2011 Plan, we recognized a $2.3 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities. We also recognized a $4.6 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. During the first six months of fiscal year 2012, we recorded a pre-tax restructuring reversal of $0.1 million relating to the Q4 2011 Plan due to a reduction in the estimated costs associated with the closure of an excess facility in the Environmental Health segment. As part of the Q4 2011 Plan, we reduced headcount by 114 employees. All employees were notified of termination and we completed all actions related to the closure of excess facility space under the Q4 2011 Plan by January 1, 2012.

Table of Contents

The following table summarizes the Q4 2011 Plan activity for the six months ended July 1, 2012:



	Severance			Closure of Excess Facility Space			Total
	(In thousands)
Balance at January 1, 2012	$	4,674		$	370		$	5,044
Change in estimates	—			(135		)	(135		)
Amounts paid and foreign currency translation	(3,233		)	(60		)	(3,293		)
Balance at July 1, 2012	$	1,441		$	175		$	1,616

We anticipate that the remaining severance payments of $1.4 million for workforce reductions will be completed by the end of the second quarter of fiscal year 2013. We also anticipate that the remaining payments of $0.2 million for the closure of excess facility space will be paid through the third quarter of fiscal year 2012, in accordance with the terms of the applicable lease.

Q2 2011 Restructuring Plan

During the second quarter of fiscal year 2011, our management approved a plan to shift resources to higher growth geographic regions and end markets (the “Q2 2011 Plan”). As a result of the Q2 2011 Plan, we recognized a $2.2 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. We also recognized a $3.4 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. As part of the Q2 2011 Plan, we reduced headcount by 72 employees. All employees were notified of termination and we completed all actions related to the closure of excess facility space under the Q2 2011 Plan by July 3, 2011.

The following table summarizes the Q2 2011 Plan activity for the six months ended July 1, 2012:



	Severance			Closure of Excess Facility Space		Total
	(In thousands)
Balance at January 1, 2012	$	1,283		$	—	$	1,283
Amounts paid and foreign currency translation	(454		)	—		(454		)
Balance at July 1, 2012	$	829		$	—	$	829

We anticipate that the remaining severance payments of $0.8 million for workforce reductions will be completed by the end of the fourth quarter of fiscal year 2012.

Previous Restructuring and Integration Plans

The principal actions of the restructuring and integration plans from fiscal years 2001 through 2010 were workforce reductions related to the integration of our businesses in order to reduce costs and achieve operational efficiencies as well as workforce reductions in both the Human Health and Environmental Health segments by shifting resources into geographic regions and product lines that are more consistent with our growth strategy. During the six months ended July 1, 2012, we paid $2.5 million related to these plans and recorded an additional charge of $0.3 million to reduce the estimated sublease rental payments reasonably expected to be obtained for an excess facility in Europe within the Environmental Health segment, as well as a charge of $0.4 million related to higher than expected costs associated with workforce reductions in Europe within the Human Health segment. As of July 1, 2012, we had $12.7 million of remaining liabilities associated with these restructuring and integration plans, primarily for residual lease obligations related to closed facilities and remaining severance payments for workforce reductions in both the Human Health and Environmental Health segments. We expect to make payments for these leases, the terms of which vary in length, through fiscal year 2022.

Table of Contents

Contract Termination Charges

We have terminated various contractual commitments in connection with certain disposal activities and have recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and costs that will continue to be incurred for the remaining terms without economic benefit to us. We recorded a pre-tax charge of $0.4 million and made payments for these obligations of $0.8 million in the first six months of fiscal year 2012. The remaining balance of these accruals as of July 1, 2012 was $1.7 million.

Interest and Other Expense, Net

Interest and other expense, net, consisted of the following:



	Three Months Ended						Six Months Ended
	July 1, 2012			July 3, 2011			July 1, 2012			July 3, 2011
	(In thousands)
Interest income	$	(150	)	$	(483	)	$	(360	)	$	(805	)
Interest expense	11,339			4,213			22,776			8,129
Other expense, net	169			541			1,772			2,703
Total interest and other expense, net	$	11,358		$	4,271		$	24,188		$	10,027

Interest and other expense, net, for the three months ended July 1, 2012 was an expense of $11.4 million, as compared to an expense of $4.3 million for the three months ended July 3, 2011, an increase of $7.1 million. The increase in interest and other expense, net, for the three months ended July 1, 2012, as compared to the three months ended July 3, 2011, was primarily due to the increase in total debt and the higher interest rates on those debt balances associated with the issuance of our 5% senior unsecured notes due 2021 (the "2021 Notes") issued during the fourth quarter of fiscal year 2011. Interest income decreased by $0.3 million for the three months ended July 1, 2012, as compared to the three months ended July 3, 2011, primarily due to lower cash balances. Other expense, net, for the three months ended July 1, 2012, as compared to the three months ended July 3, 2011, decreased by $0.4 million, and consisted primarily of expenses related to foreign currency transactions and foreign currency translation. A more complete discussion of our liquidity is set forth below under the heading “Liquidity and Capital Resources.”

Interest and other expense, net, for the six months ended July 1, 2012 was an expense of $24.2 million, as compared to an expense of $10.0 million for the six months ended July 3, 2011, an increase of $14.2 million. The increase in interest and other expense, net, for the six months ended July 1, 2012 as compared to the six months ended July 3, 2011, was primarily due to the increase in total debt and the higher interest rates on those debt balances associated with the issuance of the 2021 Notes. Interest income decreased by $0.4 million for the six months ended July 1, 2012, as compared to the six months ended July 3, 2011, primarily due to lower cash balances. Other expense, net, for the six months ended July 1, 2012 as compared to the six months ended July 3, 2011 decreased by $0.9 million, and consisted primarily of expenses related to foreign currency transactions and foreign currency translation.

Provision for Income Taxes

For the three months ended July 1, 2012, the provision for income taxes from continuing operations was $4.9 million, as compared to $6.0 million for the three months ended July 3, 2011.

For the six months ended July 1, 2012, the provision for income taxes from continuing operations was $6.3 million, as compared to $14.4 million for the six months ended July 3, 2011.

The effective tax rate from continuing operations was 12.6% and 10.2% for the three and six months ended July 1, 2012, respectively, as compared to 17.2% and 20.4% for the three and six months ended July 3, 2011, respectively. The lower effective tax rates in fiscal year 2012, as compared to fiscal year 2011, were primarily due to favorable permanent tax differences, the favorable settlement of income tax audits worldwide during the six months ended July 1, 2012, and an increase in the expected mix of profits from lower tax rate jurisdictions.

Discontinued Operations

As part of our continuing efforts to focus on higher growth opportunities, we have discontinued certain businesses. We have accounted for these businesses as discontinued operations and, accordingly, have presented the results of operations and related cash flows as discontinued operations for all periods presented. The assets and liabilities of these businesses have been

Table of Contents

presented separately, and are reflected within the assets and liabilities from discontinued operations in the accompanying condensed consolidated balance sheets as of July 1, 2012 and January 1, 2012.

We recorded the following gains and losses, which have been reported as gain (loss) on disposition of discontinued operations:

Three Months Ended

Six Months Ended

July 1,
2012

July 3,
2011

July 1,
2012

July 3,
2011

(In thousands)

(Loss) gain on disposition of Illumination and Detection Solutions business

—

(111

)